XML 59 R41.htm IDEA: XBRL DOCUMENT v3.22.0.1
Collaboration Agreements, License Agreement and Revenues - AstraZeneca Agreements - Additional Information 1 (Detail) - USD ($)
$ in Thousands
 3 Months Ended 12 Months Ended
Jul. 30, 2013
Dec. 31, 2020
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
Dec. 31, 2015
Jun. 30, 2019
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]              
Deferred Revenue   $ 6,547 $ 15,857 $ 6,547      
Deferred revenue ($3,201 and $2,907 to related parties)   6,547 15,857 6,547      
Total revenue     235,309 176,319 $ 256,577    
Product Revenue, Net [Member]              
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]              
Total revenue     47,638 72,498 1,700    
Drug Product Revenue [Member]              
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]              
Total revenue     962 8,906 (36,324)    
AstraZeneca Agreements [Member]              
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]              
Transaction price and allocated to performance obligations             $ 50,000
Revenue during period from performance obligations         42,400    
Milestone payment received     35,568        
AstraZeneca Agreements [Member] | Selling, General and Administrative Expenses [Member]              
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]              
Reversal of accrued co-promotion expenses   84,400          
Co-promotion expenses     4,700 27,200      
AstraZeneca Agreements [Member] | Drug Product Revenue [Member]              
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]              
Deferred Revenue     11,200        
Deferred revenue ($3,201 and $2,907 to related parties)     11,200        
Total revenue     $ (2,224) 4,625 0    
AstraZeneca Agreements [Member] | U.S./RoW [Member]              
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]              
Upfront, non-contingent, non-refundable and time-based payments $ 374,000            
Potential milestone payments 875,000            
Commercial sales milestone 325,000            
Shared development costs           $ 233,000  
Additional consideration based on net sales description     low 20% range        
Aggregate considerations received excluding drug product revenue     $ 439,000        
AstraZeneca Agreements [Member] | U.S./RoW [Member] | FibroGen, Inc. [Member]              
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]              
Shared development costs           $ 116,500  
AstraZeneca Agreements [Member] | U.S./RoW [Member] | Clinical and Development Milestone [Member]              
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]              
Potential milestone payments 65,000            
AstraZeneca Agreements [Member] | U.S./RoW [Member] | Regulatory Milestone [Member]              
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]              
Potential milestone payments 325,000            
AstraZeneca Agreements [Member] | U.S./RoW [Member] | Deferred Approval Milestone [Member]              
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]              
Potential milestone payments 160,000            
AstraZeneca Agreements [Member] | China [Member]              
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]              
Potential milestone payments 348,500       22,000    
Transaction price and allocated to performance obligations         22,000    
Deferred Revenue   7,000 7,900 7,000      
Proceeds from upfront, non-contingent and non-refundable payments 28,200            
Commercial sales and other events milestone 187,500            
Aggregate considerations received     77,200        
Milestone payment received         18,700    
Deferred revenue ($3,201 and $2,907 to related parties)   7,000 7,900 7,000      
Total revenue     0 (90) 90    
AstraZeneca Agreements [Member] | China [Member] | Product Revenue, Net [Member]              
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]              
Total revenue     35,600        
AstraZeneca Agreements [Member] | China [Member] | Accrued and Other Current Liabilities [Member]              
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]              
Deferred Revenue   7,000 7,900 7,000      
Deferred revenue ($3,201 and $2,907 to related parties)   $ 7,000 7,900 7,000      
AstraZeneca Agreements [Member] | China [Member] | Clinical and Development Milestone [Member]              
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]              
Potential milestone payments 15,000            
AstraZeneca Agreements [Member] | China [Member] | Regulatory Milestone [Member]              
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]              
Potential milestone payments $ 146,000            
Direct Sales [Member] | Product Revenue, Net [Member]              
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]              
Total revenue     12,070 $ 72,498 $ 1,700    
Direct Sales [Member] | China [Member] | Product Revenue, Net [Member]              
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]              
Total revenue     $ 12,100